Anti-Human EGFR x MET (Amivantamab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Amivantamab. Amivantamab binds with high specificity to EGFR and MET, particularly targeting EGFR mutations, including exon 20 insertions, and MET alterations.

Anti-Human EGFR x MET bispecific antibodies have shown promising results in cancer therapy. These antibodies target both the epidermal growth factor receptor (EGFR) and the MET receptor, which are crucial in cancer progression and resistance mechanisms. Studies have demonstrated that bispecific antibodies can inhibit proliferation, migration, and invasive growth of tumor cells more effectively than single-agent treatments. Additionally, these antibodies have been found to enhance tumor growth inhibition and downregulate both EGFR and MET receptors, highlighting their potential in combating therapeutic resistance in patients with EGFR mutations. The combination of EGFR and MET inhibition through bispecific antibodies presents a valuable strategy for overcoming resistance mechanisms and improving treatment outcomes in cancer patients^1-3.

Amivantamab (JNJ-611) is a human bispecific monoclonal antibody that targets both the EGFR and the hepatocyte growth factor receptor (HGFR/cMet). This bispecific antibody is engineered to simultaneously bind to wild-type and mutant forms of EGFR and MET, thereby blocking their phosphorylation and subsequent signaling pathways essential for cancer cell proliferation. Preclinical studies demonstrated the superior efficacy of Amivantamab in models with EGFR exon 20 insertions compared to other therapies like cetuximab or poziotinib. In clinical settings, Amivantamab has shown promise in treating patients with NSCLC, particularly those with EGFR exon 20 insertion mutations who have progressed after platinum-based chemotherapy^1,3.

EGFR and MET are widely expressed in various epithelial tissues, including lung, skin, and digestive tract linings. In cancer cells, these receptors can be overexpressed or mutated, driving tumorigenesis.

EGFR: EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG, HBEGF, hepatitis C virus MET: HGF ligand, PIK3R1, PLCG1, SRC, GRB2, STAT3, GAB1, Listeria monocytogenes internalin InlB

EGFR: P00533
MET: P08581

1. Petrini I, Giaccone G. Onco Targets Ther. 2022;15:1197-1210.
2. Neijssen J, Cardoso RMF, Chevalier KM, et al. J Biol Chem. 2021;296:100641.
3. Zhou C, Tang KJ, Cho BC, et al. N Engl J Med. 2023;389(22):2039-2051.
4. Amivantamab (JNJ-61186372) | EGFR-MET Dual Antibody | MedChemExpress. MedchemExpress.com. Accessed September 30, 2024. https://www.medchemexpress.com/amivantamab.html